Biomarker for predicting drug resistance of bruton's tyrosine kinase inhibitors and application thereof
AssigneeBeijing Friendship Hospital, Capital Medical University
InventorsYiqun Che, Junhao Wei, Xinyu Han
Life of this patent
Estimating the term…
Abstract
A biomarker for predicting drug resistance of a BTK inhibitor and an application thereof are provided in the present disclosure, relating to the technical field of biomedicine. The biomarker is SMPD1 or SPHK1; the drug resistance of BTK inhibitor refers to the drug resistance of diffuse large B cell lymphom cells to the BTK inhibitor. This biomarker is used to predict sensitivity of diffuse large B cell lymphom cells to the BTK inhibitors.
Claims1
A composition for treating diffuse large B cell lymphoma comprising a reagent for reducing an expression of sphingomyelin phosphodiesterase 1 (SMPD11 and/or sphingosine kinase 1 (SPHK11 and a Bruton's tyrosine kinase (BTK inhibitor;
- wherein
- the reagent is short hairpin ribonucleic acid (shRNA) with a nucleotide sequence as shown in SEQ ID NO.6;
- and
- the BTK inhibitor is zebutinib.
Dependencies are inferred from the claim text.